Experience of application of anti PD-1 therapy in MMR-deficiency endometrial cancer
Автор: Cham K.G., Raskin G.A., Andabekov T.T., Rodina M.K., Rutkin I.O., Kondrachuk D.M., Vinokurov V.L.
Журнал: Злокачественные опухоли @malignanttumors
Рубрика: Профилактика, диагностика и лечение онкологических заболеваний
Статья в выпуске: 2 т.8, 2018 года.
Бесплатный доступ
Currently, more and more studies show the effectiveness of anti-PD-1 therapy in tumors with a deficiency of the unpaired DNA nucleotide repair system (MMR). According to various sources in endometrial cancer, the MMR deficit is determined in 20-30 % of cases. This paper presents the experience of successful immunotherapy (anti PD-1) in a patient with metastatic endometrioid adenocarcinoma of the uterus with a deficiency of MMR.
Mmr, анти-pd-1, endometrioid adenocarcinoma, immunotherapy, anti pd-1
Короткий адрес: https://sciup.org/140243789
IDR: 140243789 | DOI: 10.18027/2224-5057-2018-8-2-60-63
